Relay Therapeutics, Inc.
RLAY
$10.63
$0.494.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -17.02% | 10.44% | |||
| Gross Profit | 27.33% | -11.67% | |||
| SG&A Expenses | 8.73% | -9.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.01% | 6.87% | |||
| Operating Income | 21.72% | -7.84% | |||
| Income Before Tax | 25.97% | -5.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.97% | -5.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.97% | -5.36% | |||
| EBIT | 21.72% | -7.84% | |||
| EBITDA | 21.74% | -8.29% | |||
| EPS Basic | 26.41% | -4.67% | |||
| Normalized Basic EPS | 23.33% | -8.21% | |||
| EPS Diluted | 26.41% | -4.67% | |||
| Normalized Diluted EPS | 23.33% | -8.21% | |||
| Average Basic Shares Outstanding | 0.60% | 0.66% | |||
| Average Diluted Shares Outstanding | 0.60% | 0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||